Resistance to HIV integrase inhibitors

Current Opinion in HIV and AIDS

Volumn 7, Issue 5, 2012, Pages 401-408

  Mesplède, Thibault ^a   Quashie, Peter K ^a,b   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

HIV 1; integrase strand transfer inhibitors; resistance mutations

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; RALTEGRAVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CELL CULTURE; CHEMICAL ANALYSIS; CLINICAL PRACTICE; CROSS RESISTANCE; DNA BINDING; DNA STRUCTURE; DRUG EFFICACY; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW;

AMINO ACID SUBSTITUTION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE;

EID: 84865634229     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328356db89     Document Type: Review

References (71)

1. Whitney JB, Lim SY, Wainberg MA. Evolutionary mechanisms of retroviral persistence. AIDS Rev 2011; 13:234-239.
2. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637-646.
3. Delelis O, Carayon K, Saib A, et al. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008; 5:114.
4. Li X, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral DNA integration. Virology 2011; 411:194-205.
5. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646- 650.
6. Engelman A, Cherepanov P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol 2012; 10:279-290.
7. Schafer JJ, Squires KE. Integrase inhibitors: A novel class of antiretroviral agents. Ann Pharmacother 2010; 44:145-156.
8. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355- 365.
9. Briz V, Garrido C, Poveda E, et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses 2009; 25:225-227.
10. Nguyen BY, Isaacs RD, Teppler H, et al. Raltegravir: The first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011; 1222:83-89.
11. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
12. Wills T, Vega V. Elvitegravir: A once-daily inhibitor of HIV-1 integrase. Expert Opin Investig Drugs 2012; 21:395-401.
13. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012; 21:523-530.
14. Kobayashi M, Nakahara K, Seki T, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008; 80:213-222.
15. Nakahara K, Wakasa-Morimoto C, Kobayashi M, et al. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res 2009; 81:141-146.
16. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605- 612.
17. Goethals O, Van Ginderen M, Vos A, et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res 2011; 91: 167-176
18. Bar-Magen T, Sloan RD, Faltenbacher VH, et al. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 2009; 6:103.
19. Bar-Magen T, Sloan RD, Donahue DA, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84:9210-9216.
20. Van Wesenbeeck L Rondelez E Feyaerts M et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a Panel Of Recombinant Viruses Derived From Raltegravir-treated Clinical Isolates. Antimicrob Agents Chemother 2011; 55321-325.
21. Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavirboosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011; 55:3517-3521.
22. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/ GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54:254-258.
23. Min S, Sloan L, Dejesus E, et al. Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1- infected adults. AIDS 2011; 25:1737-1745.
24. .Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813-821
25. Goethals O, Vos A, Van Ginderen M, et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with secondgeneration resistance profiles. Virology 2010; 402:338-346.
26. Hare S, Smith SJ, Metifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011; 80:565-572.
27. Seki T Kobayashi M Wakasa-Morimoto C et al. SGSK1349572 is a Potent Next Generation HIV Integrase Inhibitor Demonstrates A Superior Resistance Profile Substantiated With 60 Integrase Mutant Molecular Clones. 17th CROI Conference On Retroviruses Opportunistic Infections San Francisco CA; 2010.
28. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the secondgeneration integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86:2696-2705.
29. Krishnan L, Li X, Naraharisetty HL, et al. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 2010; 107:15910-15915.
30. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464:232-236.
31. Cherepanov P, Maertens GN, Hare S. Structural insights into the retroviral DNA integration apparatus. Curr Opin Struct Biol 2011; 21:249-256.
32. Maertens GN, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010; 468:326- 329.
33. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A 2000; 97:11244-11249.
34. Hare S, Vos AM, Clayton RF, et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A 2010; 107:20057-20062.
35. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV- 1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 2002; 99:6661-6666.
36. Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem 2011; 54:8407- 8420.
37. Bacchi A, Carcelli M, Compari C, et al. HIV-1 IN strand transfer chelating inhibitors: A focus on metal binding. Mol Pharm 2011; 8:507-519.
38. Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204-1214.
39. Dicker IB, Terry B, Lin Z, et al. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem 2008; 283:23599- 23609.
40. GoethalsO, Clayton R, VanGinderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82:10366-10374.
41. Hazuda DJ. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz J Infect Dis 2010; 14:513-518.
42. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011; 25:1175- 1178.
43. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194 (Suppl 1): S51-S58.
44. Johnson AA Santos W Pais GC et al. Integration requires a Specific Interaction Of The Donor DNA Terminal 50-cytosine With Glutamine 148 Of The HIV-1 Integrase Flexible Loop. J Biol Chem 2006; 281461- 467.
45. Jayappa KD, Ao Z, Yang M, et al. Identification of critical motifs within HIV-1 integrase required for importin alpha3 interaction and viral cDNA nuclear import. J Mol Biol 2011; 410:847-862.
46. Kawonga M, Blanchard K, Cooper D, et al. Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa. J Fam Plann Reprod Healthcare 2008; 34:159-164.
47. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55:4552-4559.
48. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006; 5:730- 739.
49. de Soultrait VR, Desjobert C, Tarrago-Litvak L. Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase. Curr Med Chem 2003; 10:1765- 1778.
50. Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol 2009; 485:427-433.
51. Jones G, Ledford R, Yu F, et al. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th CROI, Conference on Retroviruses and opportunistic infections, Los Angeles, California; 2007.
52. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764- 774.
53. Codoner FM, Pou C, Thielen A, et al. Dynamic escape of preexisting raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 2010; 88:281-286.
54. Armenia D, Vandenbroucke I, Fabeni L, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: A refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012; 205:557-567.
55. Winters B, Lloyd RJ, Miller M, Holodniy M. Evolution of IN inhibitor resistance mutations in patients failing elvitegravir-containing regimens. 19th CROI, Conference on retroviruses and opportunistic infections, Seattle, WA 2012, Abstract: 701.
56. Canducci F, Sampaolo M, Marinozzi MC, et al. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009; 23:455-460.
57. Charpentier C, Karmochkine M, Laureillard D, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008; 9:765-770.
58. Fransen S, Karmochkine M, Huang W, et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009; 53:4522-4524.
59. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63:795-804.
60. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist Updat 2010; 13:139-150.
61. Malet I, Fourati S, Charpentier C, et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02/AG HIV-1 subtype. J Antimicrob Chemother 2011; 66:2827-2830.
62. Sato A, Seki T, Kobayashi M, et al. In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572. 49th ICAAC, San Francisco, CA; 2009.
63. Margot NA, Hluhanich RM, Jones GS, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 2012; 93:288-296.
64. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011; 204:1811- 1815.
65. Stellbrink HJ, Reynes J, Lazzarin A, et al. Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naíve adults: 96-week results from SPRING-1 (ING112276). 19th CROI, Conference on retroviruses and opportunistic infections, Seattle, WA 2012, Abstract: 102LB.
66. .van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111-118
67. Enron J, Kumar P, Lazzarin A, et al. DTG in subjects with HIV exhibiting RAL resistance: Functional monotherapy results of VIKING Study Cohort II. 18th CROI, Conference on retroviruses and opportunistic infections, Boston, MA 2011, Abstract: 151LB.
68. Kobayashi M, Seki T, Yoshinaga T, et al. Antiviral activity in vitro of the INI, dolutegravir, against raltegravir-resistant HIV-2 mutants. 19th CROI, Conference on retroviruses and opportunistic infections, Seattle, WA 2012, Abstract: 691.
69. Boyd SD, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF/AG-infected patient. Antivir Ther 2011; 16:257-261.
70. Young B, Fransen S, Greenberg KS, et al. Transmission of integrase strandtransfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; 16:253-256.
71. Hrt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther 2011; 16:137-140.